TokenPost·

Doctors Call Moderna-Merck Melanoma Vaccine Trial Results Meaningful

3 outlets reporting
Your call?
42%
lower recurrence risk

The combination lowered the hazard of recurrence or death by 42% in a 1,137-patient trial, but an overall-survival benefit has not been established.

Share

Also covered by 2 outlets

More news